4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Thymic Carcinoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 94 ongoing clinical trials involving Thymic Carcinoma
Of the 94 trials,45 trials are in Phase II
Furthermore, 24 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Thymic Carcinoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Thymic Carcinoma, an oncology condition. The largest number of ongoing clinical trials for Thymic Carcinoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Thymic Carcinoma-related drug trials.

National Cancer Institute US: The leading ongoing Thymic Carcinoma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Thymic Carcinoma-related ongoing clinical trials.

Memorial Sloan Kettering Cancer Center, Hutchison MediPharma Ltd, CytomX Therapeutics Inc, Graduate School of Medicine / Faculty of Medicine Osaka University, and Alphamab Oncology are among other notable clinical trial sponsors involved in Thymic Carcinoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Thymic Carcinoma

Lenvatinib mesylate (Lenvima/ Kisplyx) is the key marketed drug involving Thymic Carcinoma.

Lenvatinib mesylate (Lenvima/ Kisplyx) is a pyrrolopyrimidine derivative that acts as an anti-neoplastic agent. It functions via Fibroblast Growth Factor Receptor 1 Inhibitor; Fibroblast Growth Factor Receptor 2 Inhibitor; Fibroblast Growth Factor Receptor 3 Inhibitor; Fibroblast Growth Factor Receptor 4 Inhibitor; mechanism of action. It is formulated as hard gelatin capsules for oral route of administration. Lenvima is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). Lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentioated (papillary, follicular, Hurthel cell) thyroid carcinoma refractory to radioactive iodine and Kisplyx is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy and for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy and indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Lenvatinib mesylate was first approved in 2015 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Eisai Inc.